Bacterial Chassis Stress Tolerance Patents: Who Files, Where the Gaps Sit
33.4% of all filings sit with just five assignees, while the ranked field runs 100 companies deep with a long tail of single-filing entrants. Filings rose to a peak of 98 in 2021 and fell to 34 by 2024, a -65% change over that span. Counts for 2025 and 2026 are still incomplete because publication trails filing by roughly 18 months, so the recent-looking decline should be read with that lag in mind rather than as a confirmed slowdown.
- 1CORIXA CORP16.7%
- 2RGT UNIV OF CALIFORNIA4.9%
- 3MONSANTO TECHNOLOGY LLC4.4%
- 4THE SCRIPPS RES INST3.8%
- 5UNIVERSITY OF VIENNA3.6%
See the full bacterial chassis stress tolerance analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this patent landscape
Who holds the most patents in bacterial chassis stress tolerance?
The assignee ranking covers 100 companies and research institutions, counted by patent family, with the leader holding 507 records against a fifth-place figure of 108 and a tenth-place figure of 44. The top 5 assignees combined account for 33.4% of all 3,040 records in scope, and the top 10 combined reach 42.5%, showing real concentration at the top alongside a long tail of single- or few-filing entrants. Universities and research institutes feature prominently alongside agricultural and pharmaceutical companies, reflecting the field's roots in both academic protein-engineering platforms and applied strain-engineering programs.
Is patent filing in this field growing or slowing down?
Filings rose from 46 in 2017 to a peak of 98 in 2021, then declined to 34 by 2024 — a -65% change over that three-year span. Years 2025 and 2026 currently show far fewer records, but that reflects the roughly 18-month lag between filing and publication rather than a confirmed drop in activity. Treat 2021-2024 as the most reliable recent trend and wait for 2025-2026 data to fill in before drawing conclusions about current filing pace.
What technology areas dominate bacterial chassis stress tolerance patents?
Microorganism and genetic-engineering claims under C12N appear in 91.8% of the 3,040 records, making it the dominant class by a wide margin. Peptide and protein claims (C07K, 61.6%) and medicinal-preparation claims (A61K, 55.6%) follow closely, showing that most engineered-chassis work is claimed together with a specific protein or therapeutic application rather than as a standalone host modification. Measuring and testing claims (C12Q, 43.6%) and fermentation claims (C12P, 37.2%) round out the picture, pointing to diagnostic and production-scale interests running in parallel.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Bacterial Chassis Stress Tolerance covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.